鲍曼不动杆菌临床分离株耐药性及其β-内酰胺酶类型和基因型的研究

被引:0
作者
杜蓉
机构
[1] 四川大学
关键词
鲍曼不动杆菌; β—内酰胺酶; 改良三维试验; 碳青霉烯酶; ESBLs; AmpC酶; IRTs; 金属酶; 多重PCR;
D O I
暂无
年度学位
2007
学位类型
硕士
摘要
目的:研究我院鲍曼不动杆菌对临床常用12抗菌药物的耐药情况以及耐药性与常见β-内酰胺酶类型和编码基因之间的关系。 方法:对2005年1月-5月、2006年2月-6月我院临床分离的共120株鲍曼不动杆菌通过琼脂对倍稀释法进行MIC测定;使用Cefinase纸片法进行β-内酰胺酶检测;采用改良三维试验大平皿法对β-内酰胺酶阳性菌株进行β-内酰胺酶分型检测;根据耐药表型和产β-内酰胺酶类型的不同,分别对耐IMP、FOX、CAZ和CTX的菌株进行碳青霉烯酶基因blaOXA-23、blaOXA-24的PCR检测和AmpC酶、ESBLs基因的多重PCR检测。结果:除IMP外,120株鲍曼不动杆菌对其余11种抗菌药物的耐药率均超过50%。110株鲍曼不动杆菌对三种以上抗菌药物耐药,占91.67%;这些耐药菌株大多分离自痰液,主要来自于ICU病房。120株鲍曼不动杆菌中,Cefinase纸片法检测到114株产β-内酰胺酶(95%),其中63株(55.24%)能经改良三维试验大平皿法进行酶分型。在这63株鲍曼不动杆菌中,单独产碳青霉烯酶4株(3.51%)、产ESBLs 15株(13.16%)、产AmpC酶5株(4.39%)及产IRTs 18株(15.78%);同时产碳青霉烯酶和ESBLs的有5株(4.39%),产AmpC酶和ESBLs的有9株(7.89%),同时产碳青霉烯酶和IRTs的有7株(6.14%)。在IMP中介或耐药的53株鲍曼不动杆菌中,经三维试验检测产碳青霉烯酶组16株(均为非金属碳青霉烯酶),PCR检测到11株携带blaOXA-23;三维试验检测不产碳青霉烯酶组37株,PCR检测到2株携带blaOXA-23;两组均未发现blaOXA-24。对CTX/CAZ均耐药的71株鲍曼不动杆菌中,三维试验检测产ESBLs组29株,多重PCR检测到5株阳性,分别携带blaSHV、blaCTX-M-3、blaCTX-M-14的各一株,同时携带blaSHV和blaCTX-M-14的2株;三维试验检测不产ESBLs组42株,多重PCR全部阴性。对FOX中介或耐药的109株鲍曼不动杆菌中,三维试验检测产AmpC酶组14株(占12.84%),多重PCR仅检测到1株阳性,经克隆后序列分析证实为blaCIT的上游部分序列;三维试验检测不产AmpC酶组95株,多重PCR检测到2株携带blaDHA。结论:我院鲍曼不动杆菌多重耐药常见,β-内酰胺酶产生率高,同时产多型β-内酰胺酶常见。三维试验结果以产ESBLs最多且复杂,其次是IRTs。碳青霉烯酶较单一,绝大部分携带blaOXA-23,是主要的基因型,考虑与医院感染流行有关;ESBLs、AmpC酶两种β-内酰胺酶基因的多重PCR阳性率均低,考虑与引物选择有关,故其具体产酶类型有待进一步拓展研究。本研究建立的改良三维试验大平皿法能同时进行几种常见β-内酰胺酶的筛选分型,取得了很好的效果,其推广应用的价值有待进一步研究证实。
引用
收藏
页数:134
共 20 条
[1]
Identification of a novel blaOXA-51 variant, blaOXA-92, from a clinical isolate of Acinetobacter baumannii [J].
Tsakris, A. ;
Ikonomidis, A. ;
Spanakis, N. ;
Pournaras, S. ;
Bethimouti, K. .
CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (03) :348-349
[2]
Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii [J].
Héritier, C ;
Poirel, L ;
Nordmann, P .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 (02) :123-130
[3]
Is ISABA-1 customized for Acinetobacter? [J].
Segal, H ;
Garny, S ;
Elisha, BG .
FEMS MICROBIOLOGY LETTERS, 2005, 243 (02) :425-429
[4]
Prevalence of metallo-β-lactamase among Pseudomonas aeruginosa and Acinetobacter baumannii isolated from burn wounds and in vitro activities of antibiotic combinations against these isolates [J].
Altoparlak, U ;
Aktas, F ;
Celebi, D ;
Ozkurt, Z ;
Akcay, MN .
BURNS, 2005, 31 (06) :707-710
[5]
Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina [J].
Brown, S ;
Young, HK ;
Amyes, SGB .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (01) :15-23
[6]
Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18 569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997–2001).[J].Ronald N. Jones;Helio S. Sader;Mondell L. Beach.International Journal of Antimicrobial Agents.2003, 6
[7]
Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital [J].
Gales, AC ;
Tognim, MCB ;
Reis, AO ;
Jones, RN ;
Sader, HS .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (01) :77-79
[8]
Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum β-lactamase (ESBLE) in Northern France:: a five-year multicentre incidence study [J].
Albertini, MT ;
Astagneau, P ;
Benoit, C ;
Berardi, L ;
Berrouane, Y ;
Boisivon, A ;
Cahen, P ;
Cattoen, C ;
Costa, Y ;
Darchis, P ;
Delière, E ;
Demontrond, D ;
Eb, F ;
Golliot, F ;
Grise, G ;
Harel, A ;
Koeck, JL ;
Lepennec, MP ;
Malbrunot, C ;
Marcollin, M ;
Maugat, S ;
Nouvellon, M ;
Pangon, B ;
Ricouart, S ;
Roussel-Delvallez, M ;
Vachée, A ;
Carbonne, A ;
Marty, L ;
Jarlier, V .
JOURNAL OF HOSPITAL INFECTION, 2002, 52 (02) :107-113
[9]
Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum β-lactamase VEB-1 in Pseudomonas aeruginosa [J].
Naas, T ;
Poirel, L ;
Karim, A ;
Nordmann, P .
FEMS MICROBIOLOGY LETTERS, 1999, 176 (02) :411-419
[10]
Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2 [J].
Brown, S ;
Bantar, C ;
Young, HK ;
Amyes, SGB .
LANCET, 1998, 351 (9097) :186-187